References


7. Coutu LT, Donato JL, de Nucci G. Analysis of streptokinase contents of different streptokinase products, if mortality is used as a clinical endpoint or safety, considering that some adverse events occur in the range of 1–5% or even in <1% of patients in case of cerebral bleeding.


Michael Thimme
ZLB Behring GmbH
D 35002 Marburg
Germany
Tel: +49 6421 39 4130
Fax: +49 6421 39 4146
E-mail address: michael.thimme@zlbbehring.com